US Senators and biopharma companies have warned that staff cuts at the Food and Drug Administration (FDA) are already causing regulatory delays in reviewing pending applications. The concerns come as companies like Biogen, Moderna and Incyte face challenges navigating complex regulations amid staffing shortages. With key personnel departing or reassigned, these companies believe they are experiencing difficulties in getting their products approved on time.
Source: https://endpts.com/biotech-ceos-to-cassidy-were-already-seeing-the-effects-of-fdas-staff-cuts